Johnson and Johnson posted third-quarter adjusted earnings of $2.59 a share on revenue of $25.4 billion, clearing Wall Street targets of $2.54 and $25.28 billion respectively. The beat was powered almost entirely by Tremfya, the immune-disease drug that has become the company's primary growth engine as Stelara faces generic erosion.
Tremfya carries the quarter
Pharmaceutical sales rose 7.7% to $16.76 billion. Tremfya surged 68% to $2.4 billion, well ahead of the $2.19 billion consensus, while Stelara fell 54% to $716 million, still above the $591 million analysts had modeled. Darzalex grew 16% to $4.24 billion but missed the $4.4 billion estimate. The Stelara-to-Tremfya handoff is proceeding on schedule, though the Darzalex shortfall suggests the oncology franchise is not immune to estimate creep.
Devices feel the geopolitical weight
Medical technology revenue increased just 2.5% to $8.6 billion, with international sales essentially flat. Chief Financial Officer Joe Wolk attributed the drag to the Middle East conflict, European austerity and Chinese pricing pressure "but maybe in a little bit more pronounced way." The war has not yet raised J&J's own costs, Wolk said, but it has redirected healthcare budgets in Kuwait, the United Arab Emirates and Saudi Arabia toward defense. Abiomed's Impella heart pumps also remained sluggish after a UK study questioned their use in certain high-risk coronary procedures.
Guidance moves incrementally higher
The company lifted its full-year reported sales midpoint to $101.2 billion from $101.1 billion and raised adjusted earnings guidance to $11.10 a share from $11.04. The revisions are mathematically precise and strategically minimal, a tenth of a billion in revenue, six cents in EPS. Shares have climbed 27% this year, outperforming the broader market and most healthcare peers, which suggests the market has already priced in a steady compounder with limited upside surprise.
The budget reallocation signal
Wolk's comment that sovereign wealth funds in the Gulf are shifting from premium healthcare to defense spending is the more durable data point. It is not a supply-chain story or a currency story; it is a fiscal-priority story. If the region's wealthiest health systems are deferring device purchases, the international MedTech growth algorithm that J&J and its peers have relied on for years may need a new variable.